Ascites: all 259 studies

Page 3 of 3. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.

• VSL#3 and Spontaneous Bacterial PeritonitisTerminatedNCT01701297Phase 2
• Procalcitonin in Cirrhotic Patients at High Risk for SepsisCompletedNCT01578226
• Infrared Ray Heat Treatment in Liver Cirrhosis Patients With Refractory AscitesStatus unknownNCT01558895Phase 2/3
• Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With AscitesTerminatedNCT01552590Phase 4
• ALFApump System Post Marketing Surveillance RegistryCompletedNCT01532427
• ALFApump System Versus Standard of Care in Ascites TreatmentCompletedNCT01528410Phase 3
• Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial PeritonitisTerminatedNCT01455246Phase 2/3
• The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPSCompletedNCT01440829Phase 2/3
• Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory FunctionStatus unknownNCT01438970Phase 2
• Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver CirrhosisStatus unknownNCT01421550Phase 3
• Molecular Profiling of Metastatic Cancer in Pleural Effusion and AscitesStatus unknownNCT01369992
• Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With HepatocirrhosisCompletedNCT01359462Phase 1
• Phase III Study of Tolvaptan Tablet to Treat Cirrhosis AscitesCompletedNCT01349348Phase 3
• Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With AscitesCompletedNCT01349335Phase 2
• Mechanism and the Effect of Midodrine on Portal Pressures in Patients With CirrhosisWithdrawnNCT01331785Not applicable
• Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or AscitesCompletedNCT01327235Phase 2
• Human Albumin for the Treatment of Ascites in Patients With Hepatic CirrhosisCompletedNCT01288794Phase 4
• Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural EffusionTerminatedNCT01262612Phase 2
• Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal CancersCompletedNCT01200121Phase 2
• Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory AscitesCompletedNCT01188746Not applicable
• Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or NormonatraemiaCompletedNCT01179607Phase 2
• B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related AscitesCompletedNCT01150916Not applicable
• The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational StudyWithdrawnNCT01091233
• Portal Venous Hemodynamic Changes After HepatectomyStatus unknownNCT01073345
• Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant AscitesCompletedNCT01065246Phase 2
• Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortalCompletedNCT01059396Phase 4
• Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic ResistanceCompletedNCT01030185Phase 2/3
• Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and AlbuminCompletedNCT00986817Phase 3
• Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.CompletedNCT00968695Phase 4
• Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in CirrhoticsCompletedNCT00947336Phase 3
• A Study of Bevacizumab to Prevent Malignant AscitesWithdrawnNCT00908219Phase 2
• The Automated Fluid Shunt (AFS)in Chronic Congestive Heart FailureCompletedNCT00907673Not applicable
• A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites RemovalCompletedNCT00870662Not applicable
• Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control GroupCompletedNCT00836654Phase 2/3
• Long-term Follow-up of HALT-C Sustained Virological RespondersCompletedNCT00825877
• CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial CancersCompletedNCT00822809Phase 3
• Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic PatientsWithdrawnNCT00760032Phase 4
• Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)CompletedNCT00741663Phase 4
• Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic FunctionStatus unknownNCT00657306Phase 2
• Effect of Large Volume Paracentesis on Fatigue in CirrhosisWithdrawnNCT00603200
• Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican CommunityCompletedNCT00591968Not applicable
• Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced CirrhosisCompletedNCT00570622Phase 4
• Sodium Restriction in the Management of Cirrhotic AscitesTerminatedNCT00548366Phase 4
• Acute Hemodynamics of Albumin Versus Normal Saline in CirrhosisSuspendedNCT00511394Not applicable
• Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic AscitesCompletedNCT00501722Phase 2
• Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic AscitesCompletedNCT00501566Phase 2
• Satavaptan Dose-Ranging Study in the Prevention of AscitesCompletedNCT00501384Phase 2
• Spontaneous Bacterial Peritonitis: Incidence, Risk Factors and OutcomeCompletedNCT00490217
• Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory DysfunctionStatus unknownNCT00428506Phase 2
• Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the LiverTerminatedNCT00366795Phase 3
• Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the LiverTerminatedNCT00359437Phase 3
• Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)CompletedNCT00358878Phase 3
• Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant AscitesTerminatedNCT00265863Phase 2
• The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney DysfunctionCompletedNCT00240045Phase 2/3
• Prevention of Decompensation in Liver CirrhosisStatus unknownNCT00239096Phase 4
• TIPS With Coated Stents for Refractory Ascites in Patients With CirrhosisCompletedNCT00222014Not applicable
• Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and AscitesCompletedNCT00115947Phase 2/3
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural CancerTerminatedNCT00028782Not applicable
• North American Study for the Treatment of Refractory Ascites (NASTRA)CompletedNCT00006166Phase 3

← Ascites overview